Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase 1 clinical trial of JK06 in various solid tumors…
bioAffinity Technologies today announced agreements with three accredited investors to exercise outstanding warrants, totaling 1,041,667 shares of common stock, for gross proceeds of approximately $1,302,083. In exchange, the investors will receive new unregistered warrants (New Warrants) to purchase up to…
OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a Patient Advocacy Advisory Board (PAAB) for its osteosarcoma program. The…
Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, expressed enthusiasm about the company’s growth prospects.…
Labcorp reported strong revenue and EPS growth for the second quarter of 2024, reflecting significant momentum as the company progresses into the latter half of the year. Chairman and CEO Adam Schechter highlighted the company’s expansion in oncology, women’s health,…
WuXi AppTec Reports First Half 2024 Financial Results WuXi AppTec, a global leader in R&D and manufacturing services for the pharmaceutical and life sciences sectors, has announced its financial results for the first half of 2024, ending June 30. Key…
AbbVie Announces European Approval of SKYRIZI® for Ulcerative Colitis AbbVie has received European Commission approval for SKYRIZI® (risankizumab) to treat adults with moderately to severely active ulcerative colitis (UC) who have not responded to or were intolerant of conventional or…
Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners and included new investors Canaan Partners, Monograph Capital, and…
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a five-year extension of the RADIAN® partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). This partnership aims to support vulnerable…
AIDS Healthcare Foundation (AHF) will hold an in-person and virtual press conference at the AHF booth (#111) during the 2024 International AIDS Conference (AIDS 2024) on Tuesday, July 23, at 13:15 CEST (7:15 a.m. US EDT) in Munich, Germany, at…
Rusan Pharma, an India-based pharmaceutical company specializing in addiction treatment and pain management, recently announced that the United States Food and Drug Administration (USFDA) has granted Good Manufacturing Practice (GMP) approval for its Active Pharmaceutical Ingredient (API) facility in Ankleshwar,…
The WHO is actively participating in the 25th International AIDS Conference (AIDS 2024) in Munich, Germany, and online from July 20 to 26. During a series of pre-conference sessions and WHO-led satellite events, the Organization will present its latest epidemiological…
